4-METHYL- AND 7-METHYLPHTHALAN-1-ONE DERIVATIVES OF MYCOPHENOLIC ACID

USE IN ESTABLISHING THE DISTRIBUTION OF ACETATE DERIVED HYDROGENS

N. J. McCORKINDALE* and R. L. BAXTER[†] Chemistry Department, The University, Glasgow G12 8QQ, Scotland

and

W. B. TURNER I.C.I. Pharmaceuticals, Alderley Park, Macclesfield, Cheshire SK10 4TF, England

(Received in UK 28 August 1980)


Abstract—Incorporation of acetate-[2-¹⁴C, 2-³H] into mycophenolic acid has been shown by degradative experiments to be consistent with a starter effect indicative of a tetraketide precursor.


Biosynthetic studies on mycophenolic acid, 1, date from the early incorporations of acetate- $[{}^{14}C]^1$ to recent work involving aromatic intermediates including 2 and 3^{2-4} and it now appears that the later stages can proceed via several different pathways.⁴ A number of pentaketide phenolics co-occur with 1,⁵ a new addition being the dihydroxyphthalide 4,⁶ and an alternative pathway to 3 from a pentaketide could not be excluded.⁷ However we now describe evidence from incorporation of sodium acetate-[2-¹⁴C, 2-³H] that both H-atoms of the phthalide methylene group in 1 are part of the starter acetate unit of a tetraketide derived moiety.

[†]New address: Department of Chemistry, University of Edinburgh, West Mains Road, Edinburgh EH9 3JJ, Scotland.

 \ddagger The three lactone 7a (a plausible intermediate) was obtained from this oxidation under milder conditions and was clearly distinct from the *erythro* isomer 7b obtained via the epoxide of 8.

In order to be able to determine the tritium content in the phthalide methylene group, a derivative of 1 was sought in which these protons had been specifically removed. Apart from the chosen sequence described below, two other methods were found by which this could be achieved although in less satisfactory overall yields (Scheme 1). One involved oxidation of O-methyl mycophenolic acid (5) to give the threo anhydride 6.‡ In the other, acid catalysed cyclization of 1 to mycochromanic acid 9, followed by LAH reduction to the triol 11 and oxidation with active MnO₂ afforded a separable mixture of the isomeric lactones 13 and 14. These afforded after oxidation and esterification, methyl mycochromanate 15 and the 7-methylphthalan-1-one 16 respectively. In similar fashion, MnO₂ oxidation of the triol 17 gave an inseparable 2:1 mixture of the lactones 18 and 19. (A reference sample of the latter was prepared via the carbonate 20 which was obtained, rather than 21.








by borohydride reduction of the mixed anhydride 22). The desired regioselectivity in the oxidation was achieved by using less active MnO_2 under controlled conditions giving the cyclic hemiacetal 23 as the major product (82%) from which the 7-methylphthalan-1-one 18 was obtained in high yield by further oxidation. The NMR signal for the aromatic Me group in all the above 7-methylphthalan-1-one derivatives was shifted downfield by *ca.* 0.4 ppm from that for the Me group in the isomeric 4-methylphthalan-1-ones owing to deshielding by the *ortho* carbonyl function.

Doubly labelled 1 was readily obtained from 4-day old shake flask cultures of P. stoloniferum which had been fed on the second day after inoculation with sodium

acetate-[2-¹⁴C, 2-³H] and this was degraded as indicated in Scheme 2. In order to assess the level of incorporation into the terpenoid side chain, 1 was converted into 2 and ozonized. Borohydride reduction of the product afforded the alcohols 26 and 27 which contained 60% and 39.7% respectively of the total ¹⁴C incorporated. Since each of the three labelled carbon atoms in 26 presumably carries *ca.* 13% of the ¹⁴C radioactivity, the hydroxymethyl group of 27 must be similarly labelled. In agreement with this removal of the ³H in the hydroxymethyl group of 27 by oxidation gave 28 with loss of tritium corresponding to 12% of the total in 1. The remaining 48% of ¹⁴C activity is presumably distributed over the four appropriate C atoms of the polyketide



derived phthalide nucleus, i.e. this would have been 12% per C atom if the distribution had been uniform.¹ However the high level of tritium (34%) retained in the acid 28 indicates that the methylene group must carry a higher proportion of this than the three ring carbons. An independent measurement of the tritium content in the phthalide group was obtained by conversion of 1 via 8 into the triol 17 and thence as described above and in Scheme 2 into the lactone 18. For convenience this was further oxidised with CrO₃ to the crystalline lactone acid 29 and the transformation $1 \rightarrow 29$ was accompanied by a loss of 28.5% of the tritium content, again showing the high level of tritium activity located in the phthalide methylene group.

The relative levels of radioactivity at the eight centres can be assigned as indicated in Fig. 1 and ³H:C ratios and percentages radioactivity calculated from this provide a reasonable fit for those observed (Table 1). Both the hydrogen atoms in the phthalide CH₂ group are derived from acetate [eliminating the C-Me analogue of 4 (i.e. R' = Me) as a possible intermediate] and the starter effect observed is in accord with the precursor for the phthalide nucleus normally being a tetraketide.

EXPERIMENTAL

M.ps are uncorrected. R_{fs} refer to the on silica HF₂₅₄ using the solvents indicated.




Fig. 1. Relative distribution of ¹⁴C (³H) in 1.

The anhydride 6. To a soln of 5^6 (70 mg) in 2N KOH (2 ml), an excess of KMnO₄ in 0.45 N KOH was added at 100°. After heating for a further 2 hr, the soln was filtered, acidified with 6 N HCl and continuously extracted with ether to give the anhydride 6. (10 mg, 13%), m.p. 149-151° from CHCl₃-pet. ether (iti⁹ m.p. 153°), R_f 0.55 (CHCl₃); IR (KBr) 3560, 3460, 1840, 1770 cm⁻¹; NMR (CDCl₃) 1.48 (3 H, s, Me), 2.0-2.5 (2H, m), 2.55 (3H, s, ArMe), 2.6-3.2 (5H, m, 1H exchangeable with D₂O, 2 × CH₂ and OH), 3.65 (1H, m, CHOH), 4.17 and 3.84 (ea 3H, s, OMe); MS *m/e* 364 (6%, M⁺), 346 (5), 266 (99, M-98), 99 (100, lactone ring, C₅H₇O₂). (Found: C, 59.4; H, 5.5. Calc. for C₁₈H₂₀O₈: C, 59.3; H, 5.5%).

The threo lactone 7a. When the 2 hr heating was omitted in the above procedure, prep. tlc of the crude product gave the threo hydroxylactone 7a (14% yield), m.p. 150–151° from CHCl₃-pet. ether, R_f 0.56 (CHCl₃); IR (KBr) 3480, 1755, 1604, 1203, 1130, 1075, 943, 870, 789 cm⁻¹; UV (EtOH) λ_{max} 226 nm (ϵ 20,000), 251 (ϵ 9930), 296 (ϵ 3180); NMR (CDCl₃) 1.51 δ (3H, s, Me), 2.20 (3H, s, ArMe), 2.0–2.4 (2H, m), 2.85 (1H, exchangeable with D₂O, OH), 2.5–3.1 (4H, m), 3.64 (1H, m, CHOH), 3.84 and 4.08 (ea 3H, s, OMe), 5.15 (2H, s, ArCH₂O-); MS m/e 351 (13%, M⁺), 251 (100, M-99), 221 (68), 99 (40, lactone ring C₅H₇O₂). (Found: C, 61.6; H, 6.3. C₁₈H₂₂O₇ requires C, 61.7; H, 6.3%).

The erythro lactone 7b. Compound 8 (100 mg) was allowed to stand with *m*-chloroperbenzoic acid (100 mg) in CHCl₃ (15 ml) overnight at room temp. Prep. tlc of the neutral fraction of the product gave the corresponding epoxide (75 mg, 80%), R_f 0.72 (CHCl₃); IR (CCl₄) 1768, 1741, 1124 cm⁻¹; NMR (CDCl₃) 1.41 δ (3H, s, Me), 1.7-2.1 (2H, m), 2.19 (3H, s, ArMe), 2.2-2.6 (2H, m), 2.94 (3H, br, $2 \times CH_2$), 3.62 (3H, s, MeO₂C-), 3.81 and 4.10 (ea 3H, s, OMe), 5.14 (2H, s, ArCH₃O-); MS *m/e* 364 (8%, M⁺), 333 (25, M-MeO⁺), 235 (100), 221 (48, M-MeO₂CCH₂CH₂CH₂CMe-CH⁺), 143 (23), 115 (28), 99 (28).

A soln of the epoxide (45 mg) in CF₃CO₂H (5 ml) was allowed to stand at room temp for 2 hr. Evaporation gave the erythro *lactone* 7b which crystallized from CHCl₃-pet. ether as colourless needles, m.p. 158-159°, R_f 0.53 (CHCl₃); IR (CHCl₃) 3500, 1764, 1604 cm⁻¹; IR (KBr) 3450 br, 1760, 1597, 1300, 1201, 1124 cm⁻¹; NMR (CDCl₃) 1.46 δ (3H, s, Me), 2.16 (3H, s, ArMe), 1.8-2.9 (6H, m), 2.8 (1H, s, exchangeable with D₂O, OH), 3.8 (TH, m, -CHOH), 3.78 and 4.02 (ea 3H, s, OMe), 5.05 (2H, s, ArCH₁O-). (Found: C, 61.7; H, 6.0. C₁₈H₂₂O₇ requires: C, 61.7; H, $\overline{6.3}$ %).

Mycochromanic acid (9) and mycophenolic acid lactone (10). A soln of 1 (430 mg) in 3% conc H₂SO₄ in HOAc was refluxed for

Table 1.

Compound	Dpm/mmol × 10 ⁻⁷ Compound ³ H ¹⁴ C ³ H : ¹⁴ C			Atomic ratio [†] ³ H : ¹⁴ C	$\begin{array}{l} \mbox{$$ Radioactivity$}\\ \mbox{relative to } 1^{\dagger}\\ \mbox{$$ 3$}_{\rm H} & \mbox{$$ 14$}_{\rm C} \end{array}$	
NaOAc (fed)			178	3T : 1C		
<u>1</u>	69.5	1.25	55.6	8.52T : 9.08C (8.6T : 9.08C)	100 (100)	100 (100)
<u>17</u>	68.2	1.24	55.0	8.42T : 9.0BC (8.6T : 9.08C)	98.1 (100)	99.2 (100)
29	51.0	1.25	40.8	6.25T : 9.08C) (6.0T : 9.08C)	73.4 (70)	100 (100)
27	32.1	0.75	42.6	3.70T : 5.15C (3.6T : 5.15C)	46.2 (41.9)	60.0 (56.7)
28	23.7	0.765	31.0	2.69T : 5.15C (2.6T : 5.15C)	34.1 (30.3)	61.2 (56.7)
26	35.6	0.496	71.7	4.75T : 3.93C (5T : 3.93C)	51.2 (58.1)	39.7 (43.3)

[†] Values in parenthesis are calculated on the basis of the relative distribution indicated in fig 1. 4 hr. Extraction with CHCl₃ gave 9 (380 mg, 90%), m.p. 172-175° from CHCl₃-pet. ether (lit¹⁰ m.p. 186-188°), identical (mixed m.p., IR, NMR) with an authentic sample;¹⁰ NMR (CDCl₃) 1.36 δ (3H, s, Me), 1.9 (4H, m, -CH₂-C-O-), 2.11 (3H, s, ArMe), 2.60 (4H, m, ArCH₂ and CH₂CO-O-), 3.81 (3H, s, OMe), 5.T (2H, s, ArCH₂O-); \overline{MS} m/e 320 (50%, M⁺), 302 (40, M-H₂O), 247 (70, M-HO₂CCH₂CH₂), 207 (100), 159 (60) with m^{*} corresponding to 320 - 302 and 302 -> 207. (Found: C, 63.8; H, 6.2. Calc. for C₁₁H₂₀O₆: C, 63.7; H, 6.3%).

Addition of pet. ether to the mother liquor from crystallization of 9 gave the *lactone* **10** (20 mg, 5%), m.p. 161-162° from CHCl₃pet. ether; IR (KBr) 1770, 1735, 1630, 1292, 1140 cm⁻¹; NMR (CDCl₃) 1.5 δ (3H, s, -O-C-Me), 2.0 (4H, m, CH₂-C-O-), 2.13 (3H, s, ArMe), 2.7 (4H, m, ArCH₂ and CH₂COO), 3.8 (3H, s, OMe), 5.2 (2H, s, ArCH₂O), 7.7 (TH, s, ArOH); MS *m/e* 320 (30% M⁺), 302 (28, M-H₂O), 247 (50), 207 (100), 159 (40) with m⁺ corresponding to 320 \rightarrow 302 and 302 \rightarrow 207. (Found: C, 63.8; H, 6.7. C₁₇H₂₀O₆ requires: C, 63.7; H, 6.3%). This lactone can be prepared more efficiently (68% yield) by the action of CF₃CO₂H on 1.¹¹

A soln of 10 (60 mg) in HOAc containing 3% conc H₂SO₄ was refluxed for 12 hr. CHCl₃ extraction and prep tlc using 5% MeOH in CHCl₃ as eluent gave unchanged 10 (25 mg) and 9 (30 mg, 50%).

The triol 11. A suspension of LAH (100 mg) in dry THF was added slowly to a stirred soln of 9 (200 mg) in dry THF and the mixture was refluxed for 1 hr. After decomposition of excess reagent by addition of sat aq Na₂SO₄ (2 ml) and then water (10 ml), extraction with EtOAc gave the triol 10 as a colourless oil (200 mg, 98%) which decomposed on attempted distillation, R_f 0.45 (MeOH-CHCl₃, 1:19); IR (liquid film) 3500 (broad), 1630, 1580, 1320, 1110, 1000, 770 cm⁻¹; NMR (CDCl₃) 1.10 & (3H, s, Me), 1.8 (6H, m), 2.25 (3H, s, ArMe), 2.40 (3H, s, exchangeable with D₂O), 2.5-2.8 (2H, m, ArCH₂CH₂-), 3.50 (2H, m, -CH2CH2OH), 3.64 (3H, s, OMe), 4.61 (4H, m, 2 × ArCH2OH). The triol was characterised as its oily triacetate II, b.p. 190°/0.03 mm, Rf 0.8 (CHCl₃); IR (CCl₄) 1747, 1604, 1590, 1331, 1241, 1118, 1028 cm-1; IR (KBr) 1744, 1603, 1590, 1334, 1250, 1119, 1031 cm⁻¹; NMR (CDCl₃) 1.27 δ (3H, s, Me), 1.6-2.0 (4H, m), 2.02 (6H, s, 2×OAc), 2.03 (3H, s, OAc), 2.24 (3H, s, ArMe), 2.79 (2H, t, J = 6.5 Hz, ArCH2CH2-), 3.70 (3H, s, OMe), 4.08 (2H, t, J = 5.5 Hz, -CH₂CH₂OAC), 5.19 and 5.20 (ea 2H, s, ArCH₂O-); MS m/e 436 (67%, M⁺), 408 (17), 376 (73, M-HOAC), 348 (M-28-HOAc), 334 (46, M-HOAc-CH2=C=O), 316 (69, M-2x HOAc), 235 (67), 215 (100, M- 2x HOAc-AcOCH₂CH₂), 193(95) with m* corresponding to $436 \rightarrow 376$, $376 \rightarrow 334$, $376 \rightarrow 316$ and $316 \rightarrow 215$. (Found: C, 63.8; H, 7.5. $C_{23}H_{32}O_8$ requires: C, 63.3; H, 7.4%).

Oxidation of the triol 11 to give the 4-methylphthalan-1-one 13 and the 7-methylphthalan-1-one 14. The triol 11 (160 mg) in dry acetone was stirred with freshly prepared active MnO_2^{12} (1.6 g) for 48 hr under N₂. Filtration and evaporation gave an oil, prep tlc of which gave the isomeric lactones 13 and 14.

The 4-methylphthalan-1-one 13 crystallized from CHCl₃-pet. ether in colourless prisms (33 mg, 20%), m.p. 148-150°, R_f 0.4 (CHCl₃); IR (CHCl₃) 3525, 1760, 1607 cm⁻¹; IR (KBr) 3425, 1760, 1604, 1325, 1133, 1104, 1032, 787 cm⁻¹; NMR (CDCl₃) 1.35 δ (3H, s, Me), 1.6-2.0 (2H, m, CH₂), 1.79 (4H, m, 2 × CH₂), 2.05 (1H, m, exchangeable with D₂O), 2.17 (3H, s, ArMe), 2.79 (2H, t, J = 6 Hz, Ar<u>CH₂CH₂-)</u>, 3.75 (2H, m, -CH₂OH), 3.82 (3H, s, OMe), 5.07 (2H, s. ArCH₂O-); MS m/e 306 (37%, M⁺), 288 (10, M-H₂O), 247 (98, M-HOCH₂CH₂CH₂), 207 (100), 159 (98) with m⁺ corresponding to 306 \rightarrow 288 and 207 \rightarrow 159. (Found: C, 66.8; H, 7.4. C₁₇H₂₂O₅ requires: C, 66.7; H, 7.2%).

The 7 methylphthalan-1-one 14 was obtained as a colourless oil (48 mg, 30%), b.p. 160°/0.003 mm, R_f 0.48 (CHCl₃); IR (CHCl₃) 3620, 1755, 1618 cm⁻¹; IR (KBr) 3430, 1755, 1620, 1329, 1116, 1030, 782 cm⁻¹; NMR (CDCl₃) 1.32 δ (3H, s, Me), 1.68 (4H, m, $2 \times CH_2$), 1.70 (1H, exchangeable with D₂O), 1.81 (2H, t, J = 6 Hz, CH₂), 2.50 (3H, s, ArMe), 2.80 (2H, t, J = 6 Hz, CH₂), 2.50 (3H, s, ArMe), 3.75 (3H, s, OMe), 5.05 (2H, s, ArCH₂CH₂-), 3.62 (2H, m, CH₂OH), 3.75 (3H, s, OMe), 5.05 (2H, HOCH₂CH₂O-); MS m/e⁻³06 (83%, M⁻¹), 247 (67, M-HOCH₂CH₂CH₂), 207 (93), 177 (67), 85 (100). (Found: C, 66.4; H, 7.2. C₁₇H₂₂O₅ requires: C, 66.7; H, 7.2%).

Conversion of the triol 11 into the lactones 15 and 16. A soln of the triol 11 (140 mg) in acetone (10 ml) was treated with Jones reagent (0.2 ml) for 5 min and then diluted with icewater (5 ml). Extraction with EtOAc gave a mixture of acids which was taken up in MeOH and esterified with ethereal CH₂N₂. Prep tlc gave two products, the first of which was 15 (28 mg, 19%), b.p. 165°/0.004 mm, R_f 0.45 (CHCl₃) identical (R_f , IR, NMR) with a sample prepared from 9;¹⁰ NMR (CHCl₃) including 2.12 δ (3H, s, ArMe); MS m/e 334 (58%, M⁺), 316 (49, M-H₂O), 247 (100, M-MeO₂CCH₂CH₂), 207 (99), 159 (61) with m* corresponding to $334 \rightarrow 316.$ (Found: C, 64.4; H, 6.6. Calc. for C₁₈H₂₂O₆: C, 64.7; H, 6.6%). The second product was the isomeric 7-methylphthalan-1one 16 (30 mg, 20%), b.p. 160°/0.005 mm, R, 0.50 (CHCl₃); IR (CCl₄) 1764, 1742, 1615, 1323, 1112, 1030, 1015 cm⁻¹; IR (KBr) 1760, 1740 sh, 1618, 1325, 1112, 1024, 993, 780 cm⁻¹; NMR $(CDCl_3)$ 1.30 δ (3H, s, Me), 1.84 (2H, t, J = 7.5 Hz, CH₂), 1.9-2.2 and 2.3-2.6 (ea 2H, m, CH₂), 2.52 (3H, s, ArMe), 2.86 (2H, t, J = 7.5 Hz, ArCH₂CH₂-), 3.67 (3H, s, MeO₂C-), 3.79 (3H, s, OMe), 5.08 (2H, s, ArCH₂O-); MS *m/e* 334 (100%, M⁺), 247 (59, M-MeO₂CCH₂CH₂), 208 (82), 207 (56), 177 (47), 149 (43). (Found: C, 64.4; H, 6.6. C18H22O6 requires: C, 64.7; H, 6.4%).

The triol 17. A suspension of LAH (153 mg) in dry THF (15 ml) was added at room temp during 15 min to a stirred soln of 88 (570 mg) in dry THF (15 ml) and stirring continued for 2 hr. After decomposition of excess reagent by addition of sat Na₂SO₄aq (5 ml), extraction with EtOAc gave the triol 17 as colourless prisms (370 mg, 72%), m.p. 91° from CHCl3-pet. ether, Rr 0.45 (MeOH-CHCl₃, 1:19); IR (CHCl₃) 3610, 3480, 1572 cm⁻¹; IR (KBr) 3300, 1579, 1101, 974, 722 cm⁻¹; UV (EtOH) λ_{max} 260 nm (ε 104), 275 (ε 4100), 283 (ε 4700); NMR (CDCl₃) 1.79 δ (3H, s, Me), 1.5-2.2 (4H, m, 2×CH₂), 2.31 (3H, s, ArMe), 3.35 (2H. t. J = 7 Hz, ArCH₂CH=), 3.47 (2H, t, J = 6 Hz, CH₂CH₂OH), 3.2-3.7 (3H, br, exchangeable with D_2O , $3 \times OH$), 3.66 and 3.73 (ea 3H, s, OMe), 4.67 and 4.70 (ea 2H, s, ArCH₂OH), 5.18 (1H, t, J = 7 Hz, olefinic H); MS m/e 324 (10%, M⁺), 306 (80, M-H₂O), 288 (62, M-2x H₂O), 275 (33), 247 (58, M-H₂O-HOCH₂CH₂CH₂), 207 (83, M-H₂O-HOCH₂CH₂CH=CMeCH₂), 193 (58), 85 (100) with m* corresponding to $306 \rightarrow 288$. (Found: C, 66.6; H, 8.6. $C_{18}H_{28}O_5$ requires: C, 66.6; H, 8.7%).

Attempted preparation of the 7-methylphthalan-1-one 18. The triol 17 (60 mg) was stirred in CHCl₃ with active MnO_2^{18} (600 mg) under N₂ for 24 hr, giving a product shown by IR and NMR to consist of a 2:1 mixture of the isomeric lactones 18 and 19 inseparable by tlc.

The carbonate 20. Ethyl chloroformate (0.88 ml) in THF (2.5 ml) was added to a soln of 1 (1.46 g) and Et₃N (1.28 ml) in THF (30 ml) at -10°. After stirring for 1 hr, Et₁NHCl was removed by filtration and the soln of mixed anhydride added during 30 min to a stirred soln of NaBH₄ (1.05 g) in water (10 ml) at 10-15°. The mixture was then stirred at room temp for 18 hr, acidified with 3N HCl and extracted with EtOAc to give the carbonate 20 as a colourless oil (1.68 g, 97%), b.p. 180°/0.005 mm, Rf 0.47 (CHCl₃); IR (liquid film) 3550, 3000, 1760, 1725, 1620, 1245, 1218, 1048, 775 cm⁻¹; UV (EtOH) λ_{max} 222 nm (ϵ 13,600), 247 (ϵ 7830), 291 (ϵ 1960), 308 (ϵ 1730); NMR (CDCl₃) 1.40 δ (3H, t, J = 8 Hz, $CH_3CH_2O_{-}$), 1.77 (3H, s, Me), 1.6–2.2 (4H, m, 2× CH_2), 2.24 (3H, s, ArMe), 3.40 (2H, t, J = 6.5 Hz, ArCH₂CH=), 3.55 (2H, t, J = 6 Hz, CH_2OCO_2Et), 3.84 (3H, s, OMe), 4.38 (2H, q, J = 8 Hz, $CH_3CH_2O_{-}$, 5.17 (1H, t, J = 6.5 Hz, olefinic H), 5.18 (2H, s, ArCH2O-); MS m/e 378 (<0.1%, M+), 306 (35, M-C2H4-CO₂), 288 (31), 247 (99, M-EtO₂COCH₂CH₂CH₂), 229 (46), 207 $(100, M-EtO_2COCH_2CH_2CH=CMeCH_2), 159 (57), 85 (93).$ (Found: C, 63.5; H, 7.1. C₂₀H₂₆O₇ requires: C, 63.5; H, 6.9%).

The alcohol 21. The above 20 was heated with 3N NaOH (20 ml) under reflux for 3 hr. After acidification, extraction with EtOAc gave the alcohol 21 as colourless needles (970 mg, 70%), m.p. 105–106° from EtOAc (lit¹³ m.p. 106–107°), R_f 0.45 (CHCl₃); IR (CHCl₃) 3630, 3100 br, 3016, 1742, 1631 cm⁻¹; IR (KBr) 3436, 3100 br, 1735, 1622, 1614, 1089, 1003 cm⁻¹; NMR (CDCl₃) 1.65 (1H, s, exchangeable with D₂O, -OH), 1.84 (3H, s, Me), 1.6–2.2 (4H, m, 2 × CH₂), 2.21 (3H, s, Ar<u>Me</u>), 3.46 (2H, d, J = 7.5 Hz, ArCH₂CH=), 3.65 (2H, t, J = 6 Hz, $-CH_2$ OH), 3.85 (3H, s, OMe),

5.25 (2H, s, Ar<u>CH</u>₂O-), 5.32 (1H, t, J = 7.5 Hz, olefinic H), 7.78 (1H, s, exchangeable with D₂O, Ar<u>OH</u>); MS *m/e* 306 (27%, M⁺), 288 (20, M-H₂O), 247 (87, M-HOCH₂CH₂CH₂CH₂), 229 (28), 207 (100, M-HOCH₂CH₂CH₂CH=CMeCH₂), 159 (45), 85 (100) with m⁺ corresponding to 306 \rightarrow 288, 288 \rightarrow 270, 207 \rightarrow 159. (Found; C, 66.5; H, 7.2. Calc. for C₁₇H₂₂O₅: C, 66.7; H, 7.2%).

The alcohol 19. The above 21 (60 mg) in MeOH (10 ml) was treated with an excess of ethereal CH_2N_2 for 18 hr, giving the dimethoxy alcohol 19, a colourless oil (62 mg), b.p. 165°/0.005 mm, R_f 0.4 (MeOH-CHCl₃, 1:49); IR (KBr) 3400, 1760, 1600, 1316, 1128, 1033, 994, 966, 914 cm⁻¹; NMR (CDCl₃) 1.80 & (3H, s, Me), 1.5-2.2 (5H, m, 1H exchangeable with D₂O, $2 \times CH_2$ and -OH, 2.19 (3H, s, ArMe), 3.38 (2H, s, J = 8 Hz, ArCH₂CH=), 3.59 (2H, t, J = 6.5 Hz, -CH₂OH), 3.79 and 4.04 (ea 3H, \overline{s} , OMe), 5.11 (2H, s, ArCH₂O-), 5.18 (1H, t, J = 8 Hz, olefinic H); MS m/e 320 (58%, M⁻¹), 261 (40, M-HOCH₂CH₂CH₂), 221 (73, M-HOCH₂CH₂CH=CMeCH₂), 207 (60), 85 (100). (Found: C, 67.3; H, 7.5. C₁₈H₂₄O₅ requires: C, 67.5; H, 7.6%).

The 7-methylphthalan-1-ones 18 and 28. The MnO₂ used in the following reaction was prepared as before¹² but had been stored for 12 months at room temp and humidity. A soln of 17 (97 mg) in dry CHCl₃ was stirred at room temp under N₂ with MnO₂ (1g) until 17 could not be detected by tlc (ca. 5 hr). Prep tlc gave the 7-methylphthalan-1-ol 23 as an unstable colourless oil (70 mg, 82%), R_f 0.5 (MeOH-CHCl₃, 1:19); IR (CHCl₃) 3500 br, 1655, 1600 cm⁻¹; NMR (CDCl₃) 1.78 δ (3H, br s, Me), 1.6-2.4 (6H, m, 2H exchangeable with D₂O, 2 × CH₂ and 2 × OH), 2.28 (3H, s, ArMe), 3.35 (2H, d, J = 7.5 Hz, ArCH₂CH=), 3.55 (2H, t, J = 6.5 Hz, -CH₂OH), 3.72 and 3.76 (ea 3H, s, OMe), 5.2 (2H, br s, irr at 6.4 $\delta \rightarrow$ s, ArCH₂O-), 5.25 (1H, m, olefinic H), 6.4 [1H, br s, irr 5.2 $\delta \rightarrow$ s, ArCH₁OH)-O-].

Compound 23 (70 mg) in dry CHCl₃ (15 ml) was stirred with active MnO₂ (700 mg) under N₂ for 12 hr. Filtration and evaporation gave the 7-methylphthalan-1-one 18 as an oil (65 mg, 95%); IR (CHCl₃) 3500 br, 1760, 1600 cm⁻¹; NMR (CDCl₃) 1.80 δ (3H, br s, Me), 1.4–2.3 (5H, m, 1H exchangeable with D₂O), 2.53 (3H, s, ArMe), 3.42 (2H, d, J = 6.5 Hz, ArCH₂CH=), 3.59 (2H, t, J = 6.5 Hz, -CH₂OH), 3.75 and 3.86 (ea 3H, s, OMe), 5.19 (1H, m, olefinic H), 5.40 (2H, s, ArCH₂O-).

The above 18 (65 mg) in acetone (2 ml) was treated at 0° with Jones reagent (0.2 ml) for 15 min. Crystallization of the acidic fraction of the product from CHCl₃-pet. ether gave the 7-*methylphthalan*-1-one 29 as colourless needles (55 mg, 83%), m.p. 107-110°, R_f 0.4 (MeOH-CHCl₃, 1:19); IR (CHCl₃) 3520 br, 1760, 1711, 1595 cm⁻¹; IR (KBr) 3200-2850, 1754, 1695, 1595, 1295, 1116, 1032 cm⁻¹; UV (EtOH) λ_{max} 210 nm (ϵ 16.000), 250 (ϵ 10.900), 295 (ϵ 5500); NMR (CDCl₃) 1.80 δ (3H, s, Me), 2.36 (4H, br s, 2×CH₂), 2.56 (3H, s, ArMe), 3.42 (2H, d, J = 7 Hz, ArCH₂CH=), 3.72 and 3.85 (ea 3H, s, OMe), 5.12 (1H, m, olefinic H), 5.04 (2H, s, ArCH₂O-), 9.5 (1H, br, exchangeable with D₂O, -CO₂H). (Found: C, 64.4; H, 6.8. C₁₈H₂₂O₆ requires: C, 64.7; H, 6.6%).

The p-toluidide 24. The acid 1 (520 mg), suspended in dry benzene (50 ml) was stirred with oxalyl chloride (1 ml) for 2 hr at room temp. After evaporation, the residue, in benzene (50 ml), was refluxed with p-toluidine (230 mg) for 2 hr. After washing successively with water, dil HClaq and sat NaHCO3aq, evaporation gave the phenolic p-toluidide 24 which crystallized from EtOH as colourless prisms (590 mg, 90%), m.p. 103-104°, Rf 0.45 (CHCl3); IR (Nujol 3450, 3360, 1752, 1660, 1618, 1600, 1535 cm⁻¹; UV (EtOH) λ_{max} 217 nm (ϵ 33,000), 250 (ϵ 17,400), 306 (ϵ 4500); NMR (CDCl₃) 1.82 δ (3H, s, Me), 2.05 (3H, s, $-C_6H_4Me$), 2.28 (3H, s, ArMe), 2.40 (4H, s, 2 × CH₂), 3.39 (2H, d, J = 7 Hz, ArCH₂CH=), 3.18(3H, s, OMe), 5.11(2H, s, ArCH₂O-), 5.30 (1H, t, J = 7 Hz, olefinic H), 7.14 (4H, AA'BB' system, $J = ca. 3 Hz, -C_6H_4NH_-), 7.40$ (1H, s, exchangeable with D₂O-CF₃CO₂D, NH). 7.50 (1H, br, exchangeable with D₂O, -OH). (Found: C, 70.2; H, 6.6; N, 3.5. C24H27NO5 requires C, 70.4; H, 6.7; N, 3.4%).

The p-toluidide 25. The above 16 (180 mg) in toluene (10 ml) was treated with an excess of ethereal CH_2N_2 and allowed to stand 18 hr at room temp. Filtration and evaporation gave 25 as an oil. R_f 0.5 (CHCl₃): IR (liquid film) 3390, 1750, 1659, 1600, 1635, 1315, 1132, 770 cm⁻¹; NMR (CDCl₃) 1.83 δ (3H, s, Me), 2.11 (3H,

s, $-C_6H_4Me$), 2.28 (3H. s, ArMe), 2.40 (4H, s, 2×CH₂), 3.39 (2H, d, J = 7 Hz, ArCH₂CH=), 3.74 and 4.05 (ea 3H, s, OMe), 5.05 (2H, s, ArCH₂O-), 5.22 (1H, t, J = 7 Hz, olefinic H), 7.12 (4H, AA'BB' system, J = ca 3 Hz, $-C_6H_4NH_-$), 7.37 (1H, br, exchangeable with D₂O-CF₃CO₂D, NH).

Ozonolyis of the p-toluidide 25. Compound 25 (180 mg) was ozonized in EtOAc at -80° for 30 min and the ozonide reduced by stirring with NaBH₄ (50 mg) in aqueous MeOH (1:1) at room temp for 2 hr. Extraction with EtOAc and prep tlc gave, firstly. 26 (25 mg, 30%) as colourless prisms, m.p. 114–115° from CHCl₁-pet. ether, R_f 0.4 (MeOH-CHCl₃, 1:19); IR (CHCl₃) 3435, 1623, 1598, 1510 cm⁻¹; IR (KBr) 3330, 3250, 3180, 3120, 1670, 1608, 1550, 1511, 1310, 1128, 816 cm⁻¹; NMR (CDCl₃) 2.20 (3H, d, J = 6.5 Hz, CH₃CHOH-), 1.6–2.0 (2H, m, CH₂), 3.30 (3H, s. -C₆H₄Me), $\overline{2.43}$ (2H, t, J = 6.5 Hz, -CH₂CO-), 3.21 (1H, br. exchangeable with D₂O, -OH), 3.85 (1H, m, -CHOH-), 7.20 (4H, AA'BB' system, J = ca. 3 Hz, -C₆H₄NH-), 8.10 (1H, br. exchangeable with D₂O, -CF₃CO₂D, NH). (Found: C, 69.4; H, 8.0; N, 6.9, C₁₂H₁₇NO₂ requires: C, 69.5; H, 8.3; N, 6.8%).

The second product was the *alcohol* **27** (30 mg, 30%) as colourless needles, m.p. 98-100° from CHCl₃-pet. ether, R_f 0.65 (MeOH-CHCl₃, 1:19); IR (CHCl₃) 1754, 1597 cm⁻¹; IR (KBr) 3240, 1761, 1738, 1590, 1301, 1124, 1100, 954 cm⁻¹; UV (EtOH) λ_{max} 217 nm, 249 (ϵ 5500), 295 (ϵ 1500); NMR (CDCl₃) 2.00 δ (1H, br, exchangeable with D₂O, -OH), 2.19 (3H, s, ArMe), 2.99 (2H, t, J = 6.5 Hz, ArCH₂CH₂-), 3.75 (2H, m, -CH₂OH), 3.80 and 4.08 (ea 3H, s, OMe), 5.11 (2H, s, ArCH₂O-); \overline{MS} m/e 252 (60%, M⁻¹), 234 (26, M-H₂O), 221 (100, M-HOCH₂), 220 (57), 191 (80), 163 (59), 161 (57), 133 (74), 91 (51), 77 (44) with m* corresponding to 252 -> 234, 252 -> 221, 221 -> 191, 191 -> 163, 191 -> 161 and 161 -> 133. (Found: C, 62.0: H, 6.4. C₁₃H₁₆O₅ requires: C, 61.9: H, 6.4%).

The acid 28. The alcohol 27 (17 mg) in acetone (1 ml) was treated at 5° with Jones reagent (0.05 ml) for 10 min. Crystallization of the acidic fraction of the product from CHCl₃-pet, ether gave 28 as colourless prisms (12 mg, 70%), m.p. 148-150° (lit¹⁴ m.p. 150-151°), R_f 0.15 (MeOH-CHCl₃, 1: 19). IR (CHCl₃) 1759, 1710, 1601 cm⁻¹; IR (KBr) 3000 br, 2940, 1752, 1699, 1599, 1297, 1228, 1200, 1129, 1100, 1070, 1035, 989, 965 cm⁻¹; UV (EtOH) λ_{max} 217 nm (ϵ 26,000), 250 (ϵ 5400), 295 (ϵ 1500); NMR (CDCl₃) 2.18 δ (3H, s, Me), 3.76 (2H, s, ArCH₂O-), 3.79 and 4.09 (ea 3H, s, OMe), 5.14 (2H, s, ArCH₂O-), 7.00 (1H, br, exchange-able with D₂O); MS m/e 266 (92%, M⁺), 248 (77, M-H₂O), 221 (63, M-HO₂C), 207 (100), 163 (59), 161 (57), 133 (74), 91 (51), 77 (44) with m^{*} corresponding to 266 \rightarrow 248, 221 \rightarrow 191, 191 \rightarrow 163, 191 \rightarrow 161 and 161 \rightarrow 133. (Found: C, 58.3; H, 5.2. Calc. for C₁₁H₁₄O₆: C, 58.6; H, 5.3%).

REFERENCES

- ¹A. J. Birch, R. J. English, R. A. Massy-Westropp and H. Smith, Proc. Chem. Soc. 233 (1957); J. Chem. Soc. 369 (1958).
- ²L. Canonica, W. Kroszczynski, B. M. Ranzi, B. Rindone, E. Santaniello and C. Scolastico, *Ibid.* Perkin I, 2639 (1972); C. T. Bedford, P. Knittel, T. Money, G. T. Phillips and P. Salisbury, *Canad. J. Chem.* 51, 694 (1973).
- ³C. P. Nulton, J. D. Naworal, I. M. Campbell and E. W. Grotzinger, *Anal. Biochem.* **75**, 219 (1976); L. Colombo, C. Gennari and C. Scolastico, *J. Chem. Soc.* Chem. Commun. 434 (1978).
- ⁴N. J. McCorkindale, In *The Filamentous Fungi* Vol. 2. Biosynthesis and Metabolism (Edited by J. E. Smith and D. R. Berry), Chap. 13, p. 412. Arnold, London (1976); L. Colombo, C. Gennari, D. Potenza and C. Scolastico, J. Chem. Soc. Chem. Commun. 1021 (1979).
- ⁵Cf. W. B. Turner, *Fungal Metabolites*, p. 116. Academic Press, London (1971).
- ⁶C. H. Calzadilla, I. M. Campbell and N. J. McCorkindale, Unpublished work.
- ⁷A. J. Birch, Chemisch. Weekblad. 56, 597 (1960).
- ⁸P. W. Clutterbuck and H. Raistrick, *Biochem. J.* 27, 654 (1933).
 ⁹J. H. Birkinshaw, A. Bracken, E. N. Morgan and H. Raistrick, *Ibid.* 43, 216 (1948).
- ¹⁰T. P. Seden, R. W. Turner and W. B. Turner, *Tetrahedron* 25, 4915 (1969).

¹¹Experiment carried out by Dr. C. H. Calzadilla.
¹²J. Attenburrow, A. F. B. Cameron, J. H. Chapman, R. M. Evans, B. A. Hems, A. B. A. Jansen and T. Walker, J. Chem. Soc. 1094 (1952).

 ¹³D. F. Jones and S. D. Mills, J. Medicinal Chem. 14, 305 (1971).
 ¹⁴J. H. Birkinshaw, H. Raistrick and D. J. Ross, Biochem. J. 59, 630 (1952).